BLUE - bluebird bio, Inc.
IEX Last Trade
8.76
0.180 2.055%
Share volume: 1,303
Last Updated: Thu 26 Dec 2024 08:29:29 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$8.58
0.18
2.10%
Fundamental analysis
7%
Profitability
0%
Dept financing
14%
Liquidity
47%
Performance
1%
Performance
5 Days
1.70%
1 Month
2,005.41%
3 Months
1,465.83%
6 Months
756.04%
1 Year
472.79%
2 Year
8.50%
Key data
Stock price
$8.76
DAY RANGE
$7.74 - $8.58
52 WEEK RANGE
$0.31 - $9.80
52 WEEK CHANGE
$452.48
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Andrew Obenshain
Region: US
Website: bluebirdbio.com
Employees: 520
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: bluebirdbio.com
Employees: 520
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
bluebird bio, Inc., researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc.
Recent news